Please login to the form below

Not currently logged in
Email:
Password:

Janssen

This page shows the latest Janssen news and features for those working in and with pharma, biotech and healthcare.

Boehringer builds in immuno-oncology with €1.1bn-plus OSE deal

Boehringer builds in immuno-oncology with €1.1bn-plus OSE deal

The latter are with Servier on interleukin-7 inhibitor OSE-127 and with Johnson &Johnson’s Janssen Biotech unit for FR104, a CD28-antagonist.

Latest news

More from news
Approximately 125 fully matching, plus 383 partially matching documents found.

Latest Intelligence

  • A quest for innovative solutions A quest for innovative solutions

    Janssen adds: “We spend a lot of time asking how we, as an organisation, can prepare for this future because it is happening right now. ... There are some really exciting projects out there and we are also partnering with academic institutions to use

  • Pharma deals continue to slide Pharma deals continue to slide

    Cerecor has sold its kappa opioid receptor antagonist in phase 2 to Janssen (J&J) and Xoma has licensed its interleukin 1 beta intellectual property for cardiovascular disease to Novartis plus ... 74.5 (upfront 65). Cerecor (US). J&J/Janssen (US). Asset

  • Deal Watch - May 2017 Deal Watch - May 2017

    An example is the deal between Janssen and the Japanese company Peptidream that has a peptide discovery platform. ... Peptidream (CN). Janssen (US). Licence. Peptide discovery platform. Up to 1, 150.

  • Deal Watch February 2017 Deal Watch February 2017

    Other pharma companies divesting assets this month include Janssen/J&J and Sanofi. ... Joint venture. 286.3. Janssen/ Akebia Therapeutics. HIF-targeting candidates inc AKB-5169 for IBD (pc) plus library of HIF pathway compounds for multiple therapeutic

  • An exciting outlook for pre-approval access and compassionate use An exciting outlook for pre-approval access and compassionate use

    Various projects across the industry are currently underway to establish fair and transparent mechanisms and recommendations on extremely difficult ethical decisions related to early access, including Janssen's independent review panel

More from intelligence
Approximately 5 fully matching, plus 42 partially matching documents found.

Latest appointments

More from appointments
Approximately 3 fully matching, plus 24 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 4 fully matching, plus 26 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics